Rummel 2009.

Methods	Allocation generation: not reported Allocation concealment: not reported Blinding: no ITT: no Number of dropouts: 36/549 Median follow‐up: 28 months
Participants	549 randomised, 513 evaluable, adult patients Type of lymphoma: follicular lymphoma, mantle cell lymphoma, other indolent lymphoma Stage: 96% of patients stage III/IV Previous treatment: no Mean age: 64 years (range 31 to 83 years)
Interventions	Investigational intervention: Bendamustine 90 mg/m2 on days 1 to 2, and rituximab 375 mg/m2 on day 1; every 4 weeks, up to 6 cycles Comparator intervention: Standard CHOP and rituximab 375 mg/m2 on day 1; every 3 weeks, up to 6 cycles
Outcomes	Progression‐free survival Overall survival Event‐free survival. An event was defined by a response less than a partial response, disease progression, relapse or death from any cause Time to next treatment Adverse events
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	"Of the 549 randomized patients 36 patients were not evaluable: 10 did not receive any study medication, 9 due to withdrawal of consent, 13 due to incorrect diagnosis, and 4 for other reasons." Allocation of non‐evaluable patients is not reported.
Selective reporting (reporting bias)	Low risk	Analyses were done as stated in protocol
Other bias	Unclear risk	Research funding by Roche Pharma AG Published as an abstract
Blinding of participants and personnel (performance bias) All outcomes	High risk	Participants and personnel were not blinded to allocated treatment
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported